OliX is currently developing therapeutics for CNS diseases, such as neuropathic pains and degenerative brain disorders, using its proprietary cell-penetrating asymmetric RNA platform (cp-asiRNA).
With a single intrathecal injection of its optimized therapeutic candidate, the company identified up to 90 % knockdown of gene expression in a rodent study. The siRNA was delivered not only to the spinal cord but also to multiple areas of the brain.
The most common degenerative brain diseases include Alzheimer's disease, which affects one in 100 seniors aged 65 years or older, and Parkinson's disease, a motor disturbance disease caused by loss of brain nerve cells.
Neuropathic pains occur due to damages or functional anomalies in the nervous system.
OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a range of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.
The company's core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference, which is considered the most efficient gene silencing technology.
Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration, subretinal fibrosis, and neuropathic pain.
OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference